Media & Technology
Cov-Shield (The Rise of G2) Galaxy Next Generation Inc (OTCMKTS: GAXY)
Galaxy Next Generation Inc (OTCMKTS: GAXY) is emerging as one of the most exciting plays in penny stocks that has quickly attracted an enormous and growing shareholder base who continue to accumulate at current levels. G2 management has been working hard behind the scenes paying down convertible notes to avoid dilution. They also just filed an s-8 registering restricted preferred shares for employee compensation as well as updated shareholders that they will file the annual report 10-K with the SEC and issue a press release for fiscal year end June 30, 2020 results by September 30, 2020.
G2 provides technology to the classroom of today for the generation of tomorrow and has been getting noticed for its Cov-Shield line of products that are selling at a rapid rate as school districts open up. G2 initially announced it sold over $250,000 in Cov-Shield products in its first month on the market. Since than the Company has announced at least $1.2 million in installations and purchase orders of its red hot Cov-Shield line of products.
Galaxy Next Generation Inc (OTCMKTS: GAXY) with executive offices in Toccoa, Georgia, Jacksonville, Florida, Broomfield, Colorado and Peoria, Arizona, G2 is a leading U.S. distributor of interactive learning technology hardware and software solutions that empower teachers to motivate and engage students in learning activities. G2 works hand-in-hand with educators to help them evolve how teaching and learning happens in their 21st Century Classrooms. This new approach leverages digital content, learning data, and one-of-a-kind technologies in order to create an immersive and interactive experience. G2 ultimate purpose is to motivate the student to learn. When coupled with the Company’s intimate knowledge of the learning process, its transformative new classroom technologies enable G2 to effectively partner with teachers and students to create dynamic environments that motivate students to learn. G2 distribution channel consists of 22+ resellers across the U.S. who primarily sell the Company’s products within the commercial and the K-12 education market which is the largest customer base for G2 products – comprising nearly 90% of the company’s sales. G2 is led by seasoned corporate executive Gary LeCroy who has acted in senior management positions for a multiple of public Company’s since 2004. During his time as the head of G2, Mr. LeCroy has taken the company through a multitude of evolutions. From printing services, to AV product integration to the eventual manufacturing of interactive flat panels. Mr.LeCroy’s astute management practices and way with his employees are what has driven G2 to be so successful and to experience such rapid expansion.
G2 brands include; G2 Phoenix Communicator, a school bell and intercom system that provides key information not only to your school campus but even district wide. Schools depend on their bell schedules to communicate with the students when it is time to head toward their class, get to the next class or even clean up the lab for their current class. Phoenix Communicator allows for virtually unlimited schedules playing throughout the entire school, specific zones or classrooms. The school staff may choose from over 60 included audio files or upload their own custom files to the system. The staff may even create a playlist for special events. Setting unique colors for each schedule allows easy identification on the Phoenix Communicator bell schedule calendar as well as setting exceptions for special events and holidays. 
G2 Phoenix Communicator is available in both a Cloud and on premises version and provides a map which provides a color coded visual of each zone and the ability to initiate a call to any location in the building from the map. Phoenix Communicator’s ability to connect with its devices is paramount to the system’s operation. Phoenix Communicator provides both passive and active information related to each device being online. Phoenix Communicator Desktop and Android applications display visual messages, (including audio if desired), on the screen of your PC, MAC or Interactive Flat Panel.
G2 Adjust-A-Mount Height-Adjustable Wall Mounts for Interactive Displays come in three sizes 200, 400, and 600 and are perfect for the Office, School, Healthcare, and Tradeshows. This panel is too tall. This panel is too short. With ADJUST-A-MOUNT this panel is just right! G2 patented 
ADJUST-A-MOUNT allows 15.7 inches vertical adjustment making the ADJUST-A-MOUNT the perfect addition to any panel installation. The ADJUST-A-MOUNT is available in three weight classes allowing for panels from 37 inches to 90 inches, (50 to 198 Lbs.) Smooth Height Adjustment allows for any desired display position with 15.7 inches (400 mm) of vertical travel. Match the ADJUST-A-MOUNT to the weight of your panel. With a simple turn of a bolt and included mount make attaching the panel to the mount as simple as hanging a picture.
G2 Interactive TeacherView Distance Learning Software by Radix, powered by G2 allows teachers to easily shares their screen and manage their class’s learning on school or BYOD devices, when in school or at home and assist students in real-time. G2 Interactive streamlines the learning experience and keep your finger on the classroom pulse. It allows teachers and students to share screens and video camera, Distribute content and share websites, Use multi-user whiteboard for collaborative learning, Respond silently to electronic “hand raises” Conduct surveys and quizzes, Work alongside or remotely take control of screens, View thumbnails of students’ screens in real-time, Keep students on-task and apply device usage policies. Lock screens to maximize attention and minimize distractions. Limit access by blacklisting and whitelisting websites and apps. G2 also sells Integrated Computers (coming soon). Interactive Panels and Mounts & Accessories. G2 SLIM Interactive Flat Panel by Galaxy Next Generation. The 4K resolution of the G2 SLIM panel redefines image clarity. All G2 panels come with Android 8, eShare, G2 Control by Radix, G2 Note and Draw View software application and multiple inputs. 
The G2 SLIM is available in four standard sizes, 55, 65, 75 and 86 inch models. If you have a room where a statement is really needed. We also have the 98-inch model. EShare is a wireless multi screen interaction application which makes the user experience natural and enjoyable. Each G2 Interactive Flat Panel comes pre-installed and ready to use with your PC, MAC, Chromebook, Android and IOS devices. G2 Control by Radix is a powerful remote device management license included with every G2 SLIM. All G2 SLIM panels are factory loaded with the Android 8.
To Find out the inside Scoop on GAXY Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
G2 “Cov-Shield” is a clear barrier that is easy to set up, easy to move and easy to clean! G2 Cov-Shield comes in two types. 1. Trifold which is easy to carry and setup. 2. A la carte Panels for more permanent solutions and are quickly gaining traction with multiple shools making significant bulk orders of the products. The fall school year is right around the corner and schools are working to find solutions to help maintain distance between their students. G2 “Cov-Shield” is the ideal barrier to protect personalized workspace is the perfect solution for students as school reopen.
Cov-Shield is available in a variety of sizes from 22-inch to 72-inch and is easy to set up, easy to move and easy to clean. Sales have been swift and growing exponentially. The expanded customer base for Cov-Shield has come from multiple new states including Louisiana, Kentucky, Rhode Island, Colorado, Pennsylvania, Arkansas, Illinois and Florida. Some of the benefits of Cov Shield include; Meets CDC guidelines, No assembly required – folds up flat, Student finger protection design with pinch guard, Stress protection – provides safeguard/buffer. Allows for more students per class. Easy to clean and disinfect. Easily stored – won’t lose parts. G2 initially announced it sold over $250,000 in Cov-Shield products in its first month on the market. Since than the Company has announced at least $1.2 million in installations and purchase orders of its red hot Cov-Shield line of products.
Last year G2 acquired a wholly owned subsidiary Interlock Concepts, Inc., a west coast based audio company focused on creating innovative products that provide fundamental tools used for building notification systems. Interlock Concepts, Inc., generated approximately $4 million (unaudited) in revenue through the twelve-month period ending June 30, 2019. Interlock Concepts products and services allow institutions access to intercom, scheduling and notification systems they use every day with improved ease of use. It provides an open architecture solution which allows its products to be used in many existing and new environments. Intercom, PA, Bell and control solutions are easily added and integrated with its first to market open architecture design and current software model. Its products combine elements not normally found together over a common IP network, which minimizes infrastructure requirements and reduces costs by combining systems. This strategy also places it at the forefront of school safety and communication.
G2 has been very busy recently completing successful installations of interactive panels at Newtown County Schools in Georgia and a school in south Florida. The panels were installed under purchase orders from April of approximately $550,000 from Newton County Schools, Georgia and a school in south Florida. The Newtown County public school district includes 20,000 students and 13 elementary schools, 5 middle schools and 3 high Schools and has deployed interactive touch panels campus wide. This build on the previously announced 20,000 Cov-Shield face-shields units ordered by County Public Schools of Tampa, Florida. G2 Interlock Concepts subsidiary completed installations of its Phoenix Bell and Intercom systems at six additional schools in Colorado. These successful installations fulfilled obligations from contracts that were previously awarded in the spring. Last week the Company was awarded a new $172,000 contract from Thompson County School District in Colorado. This additional school extends the existing contract between the school district and G2 to upgrade the older/current school projects. G2 also recently received a commitment for 35,000 Cov-Shield units or up to $600,000 in Cov-Shield products from a school district in southern Texas. The city is a top ten most populous city in Texas. The school district encompasses 31 schools for its more than 1,400 teachers and over 23,000 students.
Galaxy Next Generation Inc (OTCMKTS: $GAXY is emerging as one of the most exciting plays in penny stocks that has quickly attracted an enormous and growing shareholder base who continue to accumulate at current levels. 🔥🚀 https://t.co/JCgcCDujb8 pic.twitter.com/rrs289B5sG
— The Tiger 🐅 (@cooltigerx) September 20, 2020
We have a Monster Pick Coming. Subscribe Right Now!
GAXY is emerging as one of the most exciting plays in penny stocks that has quickly attracted an enormous and growing shareholder base who continue to accumulate at current levels. G2 management has been working hard behind the scenes recently paying down convertible notes to avoid dilution. The Company also filed an s-8 registering restricted preferred shares for employ compensation as well as updated shareholders that it will file its annual report 10-K with the SEC and issue a press release for its fiscal year end June 30, 2020 results by September 30, 2020. G2 provides technology to the classroom of today for the generation of tomorrow and has been getting noticed big time for its Cov-Shield line of products are selling at a rapid rate as school districts open up. G2 initially announced it sold over $250,000 in Cov-Shield products in its first month on the market. Since than Galaxy has announced at least $1.2 million in installations and purchase orders of its red hot Cov-Shield line of products. Microcapdaily started reporting on GAXY at $0.003 in early July. We will be updating on GAXY when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GAXY.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in GAXY either long or short and we have not been compensated for this article.
LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.
GAMMABODY™ PLATFORM
LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.
To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.
In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.
My big % winning day trade today was $LVTX.
All I did was follow the system.
It has a small float.
Fresh meet never pumped before.
Big News out.
Giant volume.
Why I jumped in early and took profits on the spike in volume. pic.twitter.com/2knPeC5RHz— Trader Brian Jones (@MasterBJones) June 2, 2023
As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates.
The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.
$LVTX $66mil mcap, $133mil in cash at the end of December, cash runway into 2026, median price target $13 (443% upside)
— Jake Weber (@BioStockAnalyst) June 2, 2023
Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.
Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.
$LVTX has three gamma-delta t cell drug candidates in early-stage trials, including collaboration with $SGEN for solid tumors.
— Jake Weber (@BioStockAnalyst) June 2, 2023
In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.
We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.
Revolutionizing User Experience and Driving Stock Surge
$onfo in news and float are lit pic.twitter.com/7afKMOfdz2
— …frankyboyz… (@frankyboyz77) May 26, 2023
With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.
To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ONFO just took the elevator to the top!
Now just waiting on $CYTO pic.twitter.com/OfJgNb1ty0
— 💎 DBR 💎 (@dbr_land) May 26, 2023
Evaluating Financial Performance
While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.
*says the word "AI" once
* $ONFO +76% at market open pic.twitter.com/gOLBZjlqJ2
— Commonstock (@JoinCommonstock) May 26, 2023
Investment Outlook and Future Prospects
Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.
$onfo in news and float are lit pic.twitter.com/Q8eIveRfgd
— …frankyboyz… (@frankyboyz77) May 26, 2023
About MightyDeals.com
Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.
About Onfolio Holdings Inc.
Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.
$ONFO #Ai have you seen this stock? Just came out with a competitive AI software that will fight against the tech kings #microsoft #google
— Don’t Look Down (@M_1Ball) May 26, 2023
Conclusion
Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.
$ONFO – "AI program" is laughable. Check it out on https://t.co/0LdCQCWC28. I searched for "shoes" and flower bouquets showed up. I put in a search for "dogs" and african animals came up.
Plus, lockup expiry is tomorrow, so this is a blatant pump and dump: pic.twitter.com/QnYVoDnqqr
— Adam Gefvert, CFA (@Shiningboy) May 26, 2023
We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.
The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.
To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ENVB halted up
— Antonio Costa (@ACInvestorBlog) May 18, 2023
Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.
$ENVB 💰💰💰💰💰 pic.twitter.com/qCIxiCpF0E
— FonsieTrader (@FonsieTrader) May 18, 2023
Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.
$ENVB 👇this is an important milestone for the company! The price could increase fivefold wit the time imo.
Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin
— Swingy John (@daytrader_2020) May 18, 2023
We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gino Crescoli from Pixabay
LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum
Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions
Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells
Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership
Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI
-
Uncategorized6 months agoMeta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)
-
Micro Cap Insider2 years agoMedium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT)
-
Media & Technology2 years agoHealthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward
-
Media & Technology3 years ago
AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC)
-
Media & Technology2 years agoSNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm.
-
BioPharma1 year agoAsia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space
-
Uncategorized7 months agoMeta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)
-
BioPharma2 years agoHumbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange
